Pluronic P85 Enhances the Efficacy of Outer Membrane Vesicles As a Subunit Vaccine Against Brucella Melitensis Challenge in Mice

Overview

Journal FEMS Immunol Med Microbiol

Specialties Allergy & Immunology
Infectious Diseases
Microbiology

Date 2012 Nov 21

PMID 23163875

Citations 11

Authors

Neeta Jain-Gupta

Araceli Contreras-Rodriguez

Ramesh Vemulapalli

Sharon G Witonsky

Stephen M Boyle

Nammalwar Sriranganathan

Affiliations

Soon will be listed here.

Abstract

Brucellosis is the most common zoonotic disease worldwide, and there is no vaccine for human use. Brucella melitensis Rev1, a live attenuated strain, is the commercial vaccine for small ruminants to prevent B. melitensis infections but has been associated with abortions in animals. Moreover, strain Rev1 is known to cause disease in humans and cannot be used for human vaccination. Outer membrane vesicles (OMVs) obtained from B. melitensis have been shown to provide protection similar to strain Rev1 in mice against B. melitensis challenge. In the present work, we tested the efficacy of Pluronic P85 as an adjuvant to enhance the efficacy of Brucella OMVs as a vaccine. P85 enhanced the in vitro secretion of TNF-α by macrophages induced with OMVs and P85. Further, P85 enhanced the protection provided by OMVs against B. melitensis challenge. This enhanced protection was associated with higher total IgG antibody production but not increased IFN-γ or IL-4 cytokine levels. Moreover, P85 alone provided significantly better clearance of B. melitensis compared to saline-vaccinated mice. Further studies are warranted to find the mechanism of action of P85 that provides nonspecific protection and enhances the efficacy of OMVs as a vaccine against B. melitensis.

Citing Articles

Optimizing lipopeptide bioactivity: The impact of non-ionic surfactant dressing.

Abraham A, Gyulai G, Mihaly J, Horvath A, Dobay O, Varga Z J Pharm Anal. 2025; 14(12):101020.

PMID: 39881961 PMC: 11774939. DOI: 10.1016/j.jpha.2024.101020.

Involvement of Bacterial Extracellular Membrane Nanovesicles in Infectious Diseases and Their Application in Medicine.

Lusta K, Poznyak A, Litvinova L, Poggio P, Orekhov A, Melnichenko A Pharmaceutics. 2022; 14(12).

PMID: 36559091 PMC: 9784355. DOI: 10.3390/pharmaceutics14122597.

Evaluation of immune responses to vaccines in mouse models: A systematic review.

Darbandi A, Alamdary S, Koupaei M, Ghanavati R, Heidary M, Talebi M Front Vet Sci. 2022; 9:903890.

PMID: 36118342 PMC: 9478790. DOI: 10.3389/fvets.2022.903890.

Outer Membrane Vesicles From Modulate Immune Response and Induce Cytoskeleton Rearrangement in Peripheral Blood Mononuclear Cells.

Avila-Calderon E, Medina-Chavez O, Flores-Romo L, Hernandez-Hernandez J, Donis-Maturano L, Lopez-Merino A Front Microbiol. 2020; 11:556795.

PMID: 33193138 PMC: 7604303. DOI: 10.3389/fmicb.2020.556795.

Prediction of Human Brucellosis in China Based on Temperature and NDVI.

Zhao Y, Li R, Qiu J, Sun X, Gao L, Wu M Int J Environ Res Public Health. 2019; 16(21).

PMID: 31694212 PMC: 6862670. DOI: 10.3390/ijerph16214289.

References

Vemulapalli R, Duncan A, Boyle S, Sriranganathan N, Toth T, Schurig G . Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51. Infect Immun. 1998; 66(12):5684-91. PMC: 108718. DOI: 10.1128/IAI.66.12.5684-5691.1998. View

Adone R, Francia M, Pistoia C, Petrucci P, Pesciaroli M, Pasquali P . Protective role of antibodies induced by Brucella melitensis B115 against B. melitensis and Brucella abortus infections in mice. Vaccine. 2012; 30(27):3992-5. DOI: 10.1016/j.vaccine.2012.04.009. View

Montaraz J, Winter A, Hunter D, Sowa B, Wu A, Adams L . Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies. Infect Immun. 1986; 51(3):961-3. PMC: 260994. DOI: 10.1128/iai.51.3.961-963.1986. View

Tamayo I, Irache J, Mansilla C, Ochoa-Reparaz J, Lasarte J, Gamazo C . Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation. Clin Vaccine Immunol. 2010; 17(9):1356-62. PMC: 2944445. DOI: 10.1128/CVI.00164-10. View

Collins B . Gram-negative outer membrane vesicles in vaccine development. Discov Med. 2011; 12(62):7-15. View

Boigegrain R, Cloeckaert A, Gross A, Terraza A, Liautard J, Kohler S . Major outer membrane protein Omp25 of Brucella suis is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages. Infect Immun. 2001; 69(8):4823-30. PMC: 98570. DOI: 10.1128/IAI.69.8.4823-4830.2001. View

Wang P, Johnston T . Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J Parenter Sci Technol. 1993; 47(4):183-9. View

Asaad A, Alqahtani J . Serological and molecular diagnosis of human brucellosis in Najran, Southwestern Saudi Arabia. J Infect Public Health. 2012; 5(2):189-94. DOI: 10.1016/j.jiph.2012.02.001. View

Memish Z, Balkhy H . Brucellosis and international travel. J Travel Med. 2004; 11(1):49-55. DOI: 10.2310/7060.2004.13551. View

10.

Moustafa D, Garg V, Jain N, Sriranganathan N, Vemulapalli R . Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge. Vaccine. 2010; 29(4):784-94. PMC: 3014444. DOI: 10.1016/j.vaccine.2010.11.018. View

11.

Baldwin C, Goenka R . Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection?. Crit Rev Immunol. 2007; 26(5):407-42. DOI: 10.1615/critrevimmunol.v26.i5.30. View

12.

Kabanov A, Alakhov V . Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 2002; 19(1):1-72. DOI: 10.1615/critrevtherdrugcarriersyst.v19.i1.10. View

13.

Gamazo C, Winter A, Moriyon I, Riezu-Boj J, Blasco J, Diaz R . Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of Brucella ovis and Brucella melitensis. Infect Immun. 1989; 57(5):1419-26. PMC: 313293. DOI: 10.1128/iai.57.5.1419-1426.1989. View

14.

Mallapragada S, Narasimhan B . Immunomodulatory biomaterials. Int J Pharm. 2008; 364(2):265-71. DOI: 10.1016/j.ijpharm.2008.06.030. View

15.

Pappas G, Akritidis N, Bosilkovski M, Tsianos E . Brucellosis. N Engl J Med. 2005; 352(22):2325-36. DOI: 10.1056/NEJMra050570. View

16.

Snippe H, De Reuver M, Strickland F, Willers J, Hunter R . Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity. Int Arch Allergy Appl Immunol. 1981; 65(4):390-8. DOI: 10.1159/000232780. View

17.

Allison A, Byars N . An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods. 1986; 95(2):157-68. DOI: 10.1016/0022-1759(86)90402-3. View

18.

Perkins S, Smither S, Atkins H . Towards a Brucella vaccine for humans. FEMS Microbiol Rev. 2010; 34(3):379-94. DOI: 10.1111/j.1574-6976.2010.00211.x. View

19.

Lapaque N, Takeuchi O, Corrales F, Akira S, Moriyon I, Howard J . Differential inductions of TNF-alpha and IGTP, IIGP by structurally diverse classic and non-classic lipopolysaccharides. Cell Microbiol. 2006; 8(3):401-13. DOI: 10.1111/j.1462-5822.2005.00629.x. View

20.

Delpino M, Estein S, Fossati C, Baldi P, Cassataro J . Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine. 2007; 25(37-38):6721-9. DOI: 10.1016/j.vaccine.2007.07.002. View